Clinical Features and Results of Bortezomib-Melphalan-Prednisone (VMP) as Initial Treatment in Elderly Multiple Myeloma Patients Received Lenalidomide with Dexamethasone (Len/Dex): Subgroup Analysis of Lenalidomide Registry from Korean Multiple Myeloma Working Party (KMM151)

Jae‐Cheol Jo, Ho Sup Lee, Chang Ki Min, Kihyun Kım, Je‐Jung Lee, Soo‐Mee Bang, Jin Seok Kim, Hyeon‐Seok Eom, Jae Hoon Lee, Do Hyun Yoon, Inho Kim, Ho‐Jin Shin, Yong Park, Won Sik Lee, Young Rok, Yeung‐Chul Mun, Mark Hong Lee, Hyo Jung Kim, Sung-Nam Lim, Su-Hee Cho, Seong Kyu Park, JoonHo LeeClinical 2017 · DOI

BibTeX
@inproceedings{jo2017clinical,
  author = {Jae‐Cheol Jo and Ho Sup Lee and Chang Ki Min and Kihyun Kım and Je‐Jung Lee and Soo‐Mee Bang and Jin Seok Kim and Hyeon‐Seok Eom and Jae Hoon Lee and Do Hyun Yoon and Inho Kim and Ho‐Jin Shin and Yong Park and Won Sik Lee and Young Rok and Yeung‐Chul Mun and Mark Hong Lee and Hyo Jung Kim and Sung-Nam Lim and Su-Hee Cho and Seong Kyu Park and JoonHo Lee},
  title = {{Clinical Features and Results of Bortezomib-Melphalan-Prednisone (VMP) as Initial Treatment in Elderly Multiple Myeloma Patients Received Lenalidomide with Dexamethasone (Len/Dex): Subgroup Analysis of Lenalidomide Registry from Korean Multiple Myeloma Working Party (KMM151)}},
  booktitle = {Clinical},
  year = {2017},
  doi = {10.1016/j.clml.2017.03.233},
}

Loading related content...

Figure